LWA
AXSM icon

Lowe Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

Lowe Wealth Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$3.99K – 315
2024
Q1 		$3.99K Hold
50
– – ﹤0.01% 252
2023
Q4 		$3.98K Hold
50
– – ﹤0.01% 257
2023
Q3 		$3.5K Buy
+50
New +$3.74K ﹤0.01% 251

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lowe Wealth Advisors's AXSM Position: Q2 2024 in Review

Lowe Wealth Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2024, closing a stake of 50 shares — an estimated $3.99K sold.

Lowe Wealth Advisors first reported a position in AXSM in Q3 2023 and held it in 3 quarters. The position peaked at $3.99K in Q1 2024. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

  • Lowe Wealth Advisors reported no remaining Axsome Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lowe Wealth Advisors sold 50 Axsome Therapeutics shares in Q2 2024, an estimated $3.99K.
  • Lowe Wealth Advisors first reported a position in Axsome Therapeutics in Q3 2023 and held it in 3 quarters.
  • Lowe Wealth Advisors's Axsome Therapeutics position peaked at $3.99K in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on Lowe Wealth Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.